Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis

Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of BCG

(2022) Joshua J. Meeks et al.   JOURNAL OF UROLOGY

Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer

(2022) Ian M. McElree et al.   JOURNAL OF UROLOGY

European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

(2021) Marko Babjuk et al.   EUROPEAN UROLOGY

Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”

(2020) Marc-Oliver Grimm et al.   EUROPEAN UROLOGY

Goldilocks and the BCG: Bacillus Calmette-Guérin Dose Reduction in the Age of Shortage

(2020) Christine V. Nikas et al.   EUROPEAN UROLOGY

The Health Economics of Bladder Cancer: An Updated Review of the Published Literature

(2014) Christina Yeung et al.   PHARMACOECONOMICS

An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer

(2009) Per-Uno Malmström et al.   EUROPEAN UROLOGY

The Half-Cycle Correction Explained: Two Alternative Pedagogical Approaches

(2008) David M. J. Naimark et al.   MEDICAL DECISION MAKING